All Resources
Access a curated library of reports, policy submissions, data insights, and other materials informing Canada’s life sciences ecosystem.
The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
IMC Response to PMPRB Interim Approach Consultation
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
PMPRB Notice and Comment Response
Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.
Proposed Guidelines Monitoring and Evaluation Plan
This submission responds to PMPRB’s consultation on its proposed Guideline Monitoring and Evaluation Plan GMEP, deeming it premature.
2021 Federal Pre-Budget Consultation
The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.
PMPRB Guidelines Notice and Comment
IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.
House of Commons Standing Committee on Health (HESA)
The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.
IMC Response to PMPRB 2020 Draft Guidelines
IMC critiques the June 2020 Federal Court decision that confidential third-party payments are ultra vires the Patent Act.
